Scleroderma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
MELBOURNE, Australia, Feb. 6, 2023. Certa Therapeutics (Certa) today announces ground-breaking clinical trial data for FT011, its novel therapy for the treatment of serious inflammatory and fibrotic diseases. Certa has recently completed a global... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 6, 2023 Category: Pharmaceuticals Source Type: clinical trials

Longitudinal Spatial Frequency Domain Imaging Study
Condition: Systemic Scleroderma Intervention: Other: Spatial-frequency domain imaging (SFDI) Sponsors: Boston University; Scleroderma Clinical Trials Consortium (SCTC); Fibrosis ARC: Connecting Tissues and Investigators (FCTI ARC) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2023 Category: Research Source Type: clinical trials